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Background: Breast augmentation with silicone implants is one of the most frequently performed cosmetic
surgeries worldwide. Surgical site infection (SSI) remains an important complication of this procedure. One of the
most important risk factors for SSI is the presence of microorganisms on the skin surrounding the wound.
Guidelines by the Centers for Disease Control (CDC) recommend that surgical wounds be covered with a sterile
dressing for 24 to 48 hours. However, a recent study showed that the application of a dressing for six days after
breast reduction reduced wound colonization by coagulase-negative staphylococci.
Methods/Design: A randomized clinical trial was designed to assess two protocols of postoperative wound care to
determine how the application duration of the postoperative dressing influences wound colonization in patients
undergoing breast augmentation with silicone implants. Women aged between 18 and 60 years who are
candidates for breast augmentation with silicone implants will be randomly allocated to group I (n = 48), in which
the dressing will be removed on the first postoperative day, or group II (n = 48), in which the dressing will be
removed on the sixth postoperative day. Cutaneous colonization will be assessed by cultures of samples of skin
flora taken from the wound region. The incidence of SSI, using standardized CDC criteria, and the perceptions of
patients towards the dressing will be secondary outcomes.
Discussion: An important component of SSI prevention is to minimize all possible risk factors, and the application
of postoperative dressing plays a key role in this endeavor. The results of this clinical trial may help to standardize
postoperative wound care after breast augmentation with silicone implants.
Trial registration: This trial was registered on 12 March 2012 with ClinicalTrials.gov (identifier: NCT01553604).
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The popularity of breast augmentation with silicone
implants has grown exponentially in the last decade. Since
2007, this operation is one of the most frequently
performed cosmetic surgeries worldwide. In 2012, over
330,000 new breast augmentations were performed in the
United States alone [1]. Despite advances in the surgical
technique of breast augmentation and the technology for
manufacturing breast implants, surgical site infection
(SSI) remains an important complication of this procedure
[2,3]. SSI increases morbidity, financial and personal costs,
and the possibility of operative failure, as the implant may
need to be removed to treat the infection [4].
The risk of postoperative SSI in primary augmentation
mammoplasty with silicone implants is estimated to be
between 0.1 and 2.5% [2,4-10]. These low rates of SSI make
correlations with risk factors or specific interventions
difficult, as very large sample sizes are required to determine
statistically significant correlations [11]. However, due to the
severity of the consequences of implant-related SSI, any
contribution towards understanding these risk factors will
aid in the development of strategies for preventing infection
and improving surgical outcomes [12].
One of the most important risk factors for SSI is the
presence of microorganisms on the skin surrounding the
wound [4,11,13,14]. This risk increases when alloplastic
material is used [4]. The ability of endogenous skin
bacteria to colonize mammary prostheses has been
demonstrated in vitro [15]. Bacteria from the endogenous
flora or external sources of contamination may adhere to
the implant and form an extracellular polysaccharide-rich
matrix or biofilm, which surrounds the implant [16].
Bacteria aggregate and adhere to this extracellular matrix,
enabling them to evade the host immune response and
resist systemic antibiotics. Biofilm formation facilitates
plasmid transfer among the bacteria, leading to highly
virulent organisms. The minimum inhibitory concentra-
tion of antibiotics is 1,000 times greater for biofilms than
for planktonic bacteria [17]. The seeding of a foreign body
and the subsequent formation of a biofilm are not only
difficult to diagnose, but may be very difficult to treat,
especially with routine antibiotics [18]. Studies have sug-
gested that chronic subclinical infection related to biofilms
on implants may be associated with symptomatic capsular
contracture, which is the leading cause of reoperation in
mammary prosthetic surgery [19-24].
SSIs are related to preoperative factors (such as patient
selection), intraoperative factors (such as type of surgery),
and postoperative factors. Surgical wound management
during the postoperative period greatly influences the risk
of SSI because the skin incision serves as a gateway for
microorganisms [4,20,25,26]. Bacteria can access the
operative site via the incision. They may multiply and
invade tissues to cause infection, depending on theirnumber and pathogenic interaction with the host immune
system [19]. However, few studies have justified the
normalization of this period [26].
Care of surgical incisions has long been practiced. The use
of dressings has been documented for over 4,000 years, but
Joseph Lister introduced the concept of antisepsis only in the
nineteenth century. The ideal dressing should protect the
wound from trauma and contamination, absorb secretions,
and provide the necessary compression to minimize edema
and obliterate any dead space. Furthermore, the dressing
covers unsightly operative wounds, thereby improving the
psychological wellbeing of the patient [26,27].
The standardization of postoperative wound dressings,
including those used after breast surgery, has been based
on scarce and empirical evidence [28,29]. Different
materials and techniques for the application of new
dressings have been developed, however, conventional
gauze-based dressings are still used very often [30]. A
systematic review failed to prove the superiority of any
one type of dressing over another type, or no dressing,
and suggested a need for well-designed clinical trials to
determine the ideal application time for postoperative
wound dressings, an issue that remains controversial [31].
Guidelines by the Centers for Disease Control (CDC) rec-
ommend that surgical wounds be covered with a sterile
dressing for 24 to 48 hours [25]. Subsequent postoperative
care should be individualized; there is no ideal home-care
protocol. At present, the care of postoperative wounds is
not standardized and is based on the individual experience
of each surgeon [25,26]. A recent study by Veiga-Filho et al.
[32] showed that the application of a dressing for six days
after breast reduction reduced wound colonization by
coagulase-negative staphylococci. These authors also dem-
onstrated that patients preferred to retain the same dressing
for six days and considered this method to be safe [32].
Methods/Design
Study aims
A randomized clinical trial was designed to assess two
protocols of postoperative wound care to determine how
the application duration of the postoperative dressing
influences wound colonization in patients undergoing
breast augmentation with silicone implants. The secondary
aims are to determine the SSI rates and the perceptions of
the patients regarding the comfort, convenience and safety
of the postoperative dressing. The trial will be conducted
in a double-blinded manner in a university hospital in
Brazil (Hospital das Clínicas Samuel Libânio, Universidade
do Vale do Sapucaí). This trial has been registered at
Clinicaltrials.gov (identifier: NCT01553604).
Ethical issues
The Ethical Committee of the Universidade do Vale do
Sapucaí have reviewed and approved the study protocol
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agree to sign informed consent forms will be included in
the study.
Inclusion and exclusion criteria
Patients will be recruited from the private practices of
the first three authors (DAM, DFV and JVF). Women aged
between 18 and 60 years who are candidates for breast
augmentation with silicone implants via the inframammary
fold approach will be eligible for the study. Patients
with a body mass index (BMI) above 30 kg/m2, those
on immunosuppressive therapy, those with diabetes,
those who smoke, and those with a history of breast
cancer or breast surgery will be excluded. Patients with an
indication for an areolar or axillar approach and those
who had the dressing wet will also be excluded.
Sample size
On the basis of the literature, an increase in bacterial
growth of 100 colony-forming units (CFUs) per plate
will be considered clinically significant [32]. For a
statistical power of 95% and an alpha test risk of 5%,
the sample size has been estimated to be 48 patients
per study arm.
Group assignment, randomization and allocation
concealment
Patients will be randomly allocated to group I (n = 48),
in which the dressing will be removed on the first
postoperative day, or group II (n = 48), in which the
dressing will be removed on the sixth postoperative day.
Allocation will be determined by a random, computer-
generated sequence (Bioestat 5.0, Instituto Mamirauá,
Belém, PA, Brazil). An opaque envelope with the patient
number will be opened on the first postoperative day to
reveal the allocation of the patient.
Procedures and interventions
Patients will be instructed to bathe before surgery with a
4% chlorhexidine-based detergent (Rioquímica Indústria
Farmacêutica Ltda., São José do Rio Preto, Brazil) [33]. In
the operating room, antisepsis of the surgical site will be
performed with a 0.5% chlorhexidine solution in alcohol
(Rioquímica Indústria Farmacêutica Ltda., São José do Rio
Preto, Brazil) [34]. The nipple areola complexes will remain
uncovered during the operation; sterile tapes will not be
used to cover them, since this is not the standardized
procedure in our hospital. Patients will undergo breast
augmentation under general anesthesia. All patients will
receive prophylactic antibiotics (cefazolin - União Química
Farmacêutica Nacional S.A., São Paulo, Brazil) [35].
The surgical approach will be via the inframammary
fold. Implants (Silimed Indústria de Implantes Ltda., Rio
de Janeiro, Brazil) will be placed in the subglandular,submuscular or subfascial position, depending on which is
the best course of action for a given patient. The surgical
site will be cleaned with sterile saline after the surgery. A
sample of skin flora will be obtained for semiquantitative
culture before the application of a dressing over the
surgical incision.
The dressing will consist of four layers of cotton gauze,
covered with micropore tape. The surgical team will not
know to which group the patient belongs. On the first
postoperative day, the allocation envelopes will be opened.
If the patient is allocated to group I, the dressing will be
removed, and a sample will be harvested for culture. The
patient will be instructed to return to their normal
personal hygiene routine and return on the sixth day for
reassessment and collection of samples for culture. If the
patient is allocated to group II, she will be instructed
to not wet the bandage for six days, when it will be
removed and a sample will be harvested for culture.
Thus, samples of the skin flora will be obtained in
the operating room just before placement of the
dressing and after removal of the dressing. Additional
samples will be obtained on the sixth postoperative
day from patients in group I.
Method of sample collection
A sterile fenestrated paper field with a standard 5 cm
per 10 cm area will be placed over the surgical wound
on the right breast. A sterile swab soaked in sterile saline
will be passed across the predetermined area in a
standardized manner. This swab will be placed in a sterile
tube containing 1.0 ml of sterile saline and immediately
transferred to the laboratory.
Culture methodsStandard culture methods will be used
for the identification of microorganisms [36]. Aliquots of
0.2 ml from each sample will be plated on agar medium
hypertonic mannitol (HiMedia Laboratories Pvt. Ltd.,
Mumbai, India) to culture Staphylococcus sp., on blood
agar (HiMedia Laboratories Pvt. Ltd., Mumbai, India) to
identify hemolytic colonies, on eosin-methylene blue agar
(HiMedia Laboratories Pvt. Ltd., Mumbai, India) to identify
Enterobacteriaceae, and on Sabouraud agar supplemented
with chloramphenicol (HiMedia Laboratories Pvt. Ltd.,
Mumbai, India) (0.05 mg/ml) to detect fungi. The plates
will be incubated in an aerobic atmosphere at 37°C. After
48 hours, a microbiologist will assess the plates. The lab
technicians and microbiologist will not know which group
each sample belongs to.
Culture results will be expressed as CFUs per plate.
When a result exceeds 300 CFUs, it will be recorded
as ‘>300 CFU/plate’. Staphylococci will be identified
as coagulase-negative staphylococci or Staphylococcus
aureus, on the basis of the results of Gram staining,
the presence of hemolysis, and the results of the co-
agulase test.
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duration
Patients will be evaluated weekly for four weeks, and
then re-evaluated at six months and one year after the
operation. The CDC definition and classification of SSIs
will be used. As the surgery involves the implantation of
prostheses, an SSI is defined as an infection that occurs
within one year after the surgery [37]. The patients
will use a five-point scale to classify the dressing in
terms of comfort, practicality and safety. This assessment
will be done at the postoperative week two visit for
each patient.
Outcomes
The primary outcome will be cutaneous colonization,
expressed as the number of CFUs. The incidence of SSI
and the perceptions of patients towards healing will be
secondary outcomes. Participation will be completed at
one year after surgery, after evaluation for the presence
of infection.
Statistical analysis
The Mann–Whitney U test will be used to test the
homogeneity of the groups in terms of age, BMI and
duration of surgery. The Friedman test will be used to
compare the number of CFUs in the samples collected
before, and one and six days after the application of the
dressing in group I. If there is a significant difference
between these times, then the Friedman test will be
supplemented with the multiple comparisons test to
determine at which time points significant differences
appeared. In group II, the Wilcoxon test will be used
to compare the number of CFUs in samples collected
before the dressing and on the sixth postoperative
day. The Mann–Whitney U test will be used to com-
pare groups I and II in terms of the number of
CFUs before and six days after the application of the
dressing. Tests will always be applied independently
for each medium used.
The Fisher test will be used to compare groups I and II in
terms of the rates of infection. The Kolmogorov-Smirnov
test will be used to compare the two groups in terms of the
perceptions of the patients regarding the comfort, safety
and practicality of the dressings. All statistical analyses will
be performed using SPSS software (version 18, SPSS Inc.,
Chicago, United States of America). A P value ≤0.05 will be
considered to be statistically significant.
Discussion
As breast augmentation with silicone implants has become
a common procedure, risks factors for complications
associated with this procedure must be investigated in
detail to improve procedural safety. As modern proto-
cols and guidelines should be based on the principlesof evidence-based medicine, well-designed randomized
clinical trials are essential to guide or adjust clinical
practice [28].
Attention to the skin incision in breast augmentation is
warranted, as this incision acts as a gateway for microor-
ganisms present on the surrounding skin or in external
sources of contamination. Incisions for insertion of breast
implants are most commonly placed in the inframammary
fold, areola or axilla [38,39]. Each of these different inci-
sions traverse through the breast ducts at different levels,
providing for different potential amounts of contamination
by breast duct bacteria-colonized material [40]. However,
there is not a clear relationship between incision location
and SSI, and literature on this issue is controversial. Wiener,
in a review of 430 patients who underwent augmentation
surgery, found a significantly higher incidence of capsular
contracture when a periareolar incision was used, and he
hypothesized that this could be due to bacterial contamin-
ation from contact with the endogenous bacteria within
the breast tissue [40]. Jacobson et al., in a retrospective
chart review of 197 primary breast augmentation patients,
observed that transaxillary incisions produced the highest
incidence of contracture (6.4%), followed by periareolar
(2.4%) and inframammary (0.5%), with a statistically
significant difference [41]. Stutman et al. performed a
chart review on 619 patients who underwent primary
breast augmentation, and found a trend of increased rate
of capsular contracture when the inframammary incision
was used, but this was without statistical significance
[39]. The inframammary incisions have been the most
commonly used for primary augmentation mammaplasty,
since it is the simplest and most straightforward approach
[38-40]. For this reason, this was the incision of choice for
the current trial.
The use of biomaterials and the increased pathogenicity
of bacteria enable colonization of the implant even when
the bacterial load is relatively low. It is exceedingly difficult
to control bacterial growth after implant colonization has
occurred, and this difficulty tends to increase the infection
risk [4]. Subclinical implant infection is related to the
development of bacterial biofilms and severe capsular
contracture around the implant, which are the leading
causes of reoperation in breast augmentation [19]. The
need to remove the implant can cause psychological
trauma to the patient [2]. For these reasons, implant
subclinical infection has become a focus of substantial
research [19,20].
Bacteria are responsible for most postoperative infections
that occur after breast augmentation when implants are
used. Gram-positive cocci are part of the skin flora,
especially in the upper portion of the trunk, and they
account for many implant-related SSIs [42]. Cultures
of mammary tissue collected during breast surgery
demonstrate that these bacteria are the most frequent
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opportunistic agents, such as fungi, Gram-negative bacteria
and atypical mycobacteria, have also been described
[43-45]. Therefore, we have opted to culture these organisms
as well.
An important component of SSI prevention is to
minimize all possible risk factors. The application of
postoperative dressing plays a key role in this endeavor
[12]. However, it is difficult to demonstrate gains related
to the use of dressings for ensuring clean wounds and
lowering the infection rate [46]. For this reason, we chose
the rate of skin colonization, which is related to the SSI
rate [4,11,13,14], as the primary focus of this study.
The opinion of the patients regarding the proposed
treatment is an important factor in the quality of care.
Two different surgical dressing strategies are proposed,
and determining patients’ perceptions regarding their
comfort, convenience and safety is a secondary goal
of this study. The results of this clinical trial may
help to standardize postoperative wound care after breast
augmentation with silicone implants.Trial status
Recruitment began in April, 2012. A total of 69 patients
have been enrolled in this study and have undergone
breast augmentation with silicone implants. All patients
will be monitored for the presence of infection until one
year after their operation.
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